Late-Breaking Clinical Trials V: Interventional Cardiology
Tuesday, March 16, 10:30 AM - 12:00 PM
Organizers of ACC.10 have highlighted this session as potentially having some practice-changing results. Researchers will present three-year follow up data from the DEDICATION trial, which compared drug-eluting stents (DES) with bare-metal stents (BMS) in STEMI patients. Not everyone is convinced that DES is the way to go in this patient population. We'll see.
In addition, five-year data are being presented from the PASSION trial, which compared a DES with a BMS in STEMI patients. It will be exciting to hear the results of these two trials and whether they stand in agreement for the use or non-use of DES in STEMI patients.
Also, results from the PLATO trial could change the way surgeons perform CABG. This trial tested ticagrelor against clopidogrel in patients undergoing CABG. Ticagrelor is a reversible agent and holds some advantages over clopidogrel in certain clinical scenarios. Preliminary data from PLATO were promising for the drug. It will be interesting to discover, however, whether or not the initial positive findings held up over time and whether those results can be applied to patients undergoing PCI.
Following each abstract presentation, a panel of distinguished experts will debate the results. The abstracts are:
Location: Murphy Ballroom
Panelists:
Gregg W. Stone, MD, New York
David J. Moliterno, MD, Lexington, Ky.
Gennaro Sardella, MD, Rome, Italy
William W. O'Neill, MD, Miami
Joseph F. Sabik, MD, Cleveland
Organizers of ACC.10 have highlighted this session as potentially having some practice-changing results. Researchers will present three-year follow up data from the DEDICATION trial, which compared drug-eluting stents (DES) with bare-metal stents (BMS) in STEMI patients. Not everyone is convinced that DES is the way to go in this patient population. We'll see.
In addition, five-year data are being presented from the PASSION trial, which compared a DES with a BMS in STEMI patients. It will be exciting to hear the results of these two trials and whether they stand in agreement for the use or non-use of DES in STEMI patients.
Also, results from the PLATO trial could change the way surgeons perform CABG. This trial tested ticagrelor against clopidogrel in patients undergoing CABG. Ticagrelor is a reversible agent and holds some advantages over clopidogrel in certain clinical scenarios. Preliminary data from PLATO were promising for the drug. It will be interesting to discover, however, whether or not the initial positive findings held up over time and whether those results can be applied to patients undergoing PCI.
Following each abstract presentation, a panel of distinguished experts will debate the results. The abstracts are:
- Randomized Comparison of Angiojet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting to Direct Stenting Alone in Patients with Acute Myocardial Infarction: the Jetstent Trial.
- Long-term Outcome after Drug-Eluting versus Bare-Metal Stent Implantation in Patients with ST-Elevation Myocardial Infarction. Three-year follow-up of the DEDICATION Trial
- Five-Year Follow-up After Primary Percutaneous Coronary Intervention with A Paclitaxel-eluting Stent Versus A Bare-metal Stent in Acute ST-segment Elevation Myocardial Infarction. A Follow-up Study of the PASSION Trial.
- Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results from the PLATO Trial
- A Randomized Trial Radial Artery Grafts versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery: VA Cooperative Study
Location: Murphy Ballroom
Panelists:
Gregg W. Stone, MD, New York
David J. Moliterno, MD, Lexington, Ky.
Gennaro Sardella, MD, Rome, Italy
William W. O'Neill, MD, Miami
Joseph F. Sabik, MD, Cleveland